Navigation Links
Targeting tumor behavior may lead to new liver cancer drugs
Date:6/18/2009

COLUMBUS, Ohio Ohio State University cancer researchers have used computational and genomic methods to identify possible anti-cancer agents that may block a particular kind of tumor behavior. The agents target multiple genes associated with that behavior at one time.

The researchers wanted to find agents that might reverse the gene changes associated with invasive liver cancer and perhaps stop liver tumors from spreading in the body. Such therapy could greatly improve patient survival, the researchers say.

The findings are published online in the journal Cancer.

"This is an exciting new way to find potentially useful anti-cancer agents," says principal investigator Dr. Tushar Patel, director of hepatology and a researcher with Ohio State's Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute.

"For nearly two decades, cancer drug discovery has sought agents that block a single molecular target or pathway," he says. "Our approach identifies agents that could potentially block tumor progression by striking multiple genes that are associated with a particular cancer-related behavior."

New drugs for liver cancer are needed because the disease is widespread worldwide. The most common type of liver cancer, hepatocellular carcinoma, causes 630,000 deaths every year worldwide, and the incidence is rising in many countries, including the United States.

Only one drug is presently approved for treating advanced liver cancer, Patel says. He notes that several new agents are in development for the disease, but each affects just one or another of the many processes that are altered in liver cancer cells.

"We believe that targeting a certain type of tumor behavior might be helpful for liver cancer because many different biochemical pathways in tumor cells can be involved. Most targeted agents affect only one pathway, so a combination of drugs may be needed. Alternatively, new agents that hit multiple targets simultaneously could be used," he says.

Patel and his colleagues began their study by identifying the gene changes present in liver cancers that had invaded neighboring blood vessels.

The researchers then looked for agents that could reverse these changes as a group. They did this using a database called the connectivity map, a collection of data sets that offers a way to compare gene changes caused by a disease with gene changes caused by different chemicals or drugs.

"We queried the gene changes present in invasive liver cancer cells against the connectivity map and looked for compounds that had an opposite effect on these changes," Patel says. "If genes 'A, B and C' were increased in our tumor cells, we wanted to find an agent that decreased genes 'A, B and C'," he says.

Their search identified two compounds: Resveratol, a component of red wine that recently and coincidentally was shown by others to inhibit the ability of liver cancer cells to invade tissues and metastasize, and 17-allylamino-geldanamycin (17-AAG), which has shown anticancer activity in some solid tumors but has not been tested in liver cancer.

Last, the researchers used laboratory tests to verify that the two compounds actually did alter the invasive ability of liver cancer cells.

"This approach is exciting because it can be applied to any well-defined disease behavior," Patel says. "It might also improve the approach to drug discovery and design if some agents were modified to select for a particular genomic profile rather than a single chemical target.

"Overall," he says, "this could be a more relevant way of looking at cancer because we want to block certain disease changes and specific effects such as invasion, metastasis or chemotherapy resistance."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
2. Targeting the more lethal form of the cancer rhabdomyosarcoma
3. Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions.
4. Stem Cell Study Offers Hope for Targeting Tumors
5. Migraine prevention by targeting glutamate receptors?
6. Targeting oxidized cysteine through diet could reduce inflammation and lower disease risk
7. Deadly in Pink: New Report Warns Big Tobacco Has Stepped Up Targeting of Women and Girls
8. Targeting the protein AEG1 impairs human liver cancer growth in mice
9. Tobacco Companies Targeting Teens, Study Says
10. APIC 2009 Targeting Zero Initiative Offers Practical Tools, Evidence-Based Elimination Strategies to Prevent the Deadliest Healthcare-Associated Infections
11. Targeting Cancers Own Stem Cells to Fight Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation Act (BCRA), ... Care Act (ACA), would result in 22 million Americans losing their health insurance by ... 20 million Americans have gained health insurance under the ACA, and from 2013 to ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... ... ... Two residents from the Gardant-managed assisted living and memory care communities in ... to protect Medicaid funding. , The video, which was produced by the American Health ... and Cathy Schwarz, a couple who is still able to see each other every ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR News is looking for ... guidebook. This guidebook offers an excellent branding and exposure opportunity for the author ... and how-to’s that fall into the following categories:, ,     Media ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... Fabrykiewicz Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and ... offered their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... BOSTON , June 16, 2017  Exactly 50 years ... kicked off what later became known as the San Francisco ... www.northernlight.com ) is unveiling two radical innovations in strategic market ... summer.  This announcement marks the beginning of Northern Light,s "Summer ... ...
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
Breaking Medicine Technology: